전역
중국
시놉시스
Novotech, the Asia Pacific centered biotech specialist CRO, presents “The Next Big Thing in Cancer Care” expert panel webinar in collaboration with eChinaHealth and the ASCO Breakthrough program committee.
Novotech’s Asia Pacific operations support expedited oncology clinical trials by offering access to vast patient populations, deep local regulatory knowledge, an extensive site and KOL network, and data quality excellence.
Novotech’s Asia Pacific operations support expedited oncology clinical trials by offering access to vast patient populations, deep local regulatory knowledge, an extensive site and KOL network, and data quality excellence.
스크립트
The webinar is moderated by Dr. Peter Yu, Physician-in-Chief, Hartford HealthCare, ASCO President for 2014-2015 term
The program features:
Drugging the Undrugable
- Dr. Lillian Siu, Professor, University of Toronto; Chair, Program Committee, ASCO Breakthrough 2023
CAR-T and Adoptive Cell Therapies
- Dr. David Lebwohl, CMO, Intellia
Therapeutics Precision Oncology, AI and Next Generation Multiomic Technology
- Dr. Melvin Chua Lee Kiang, Associate Professor, National Cancer Centre Singapore; Chair-Elect, Program Committee, ASCO Breakthrough 2023
PANEL DISCUSSION:
MODERATOR:
- Peter Paul Yu, MD, FACP, FASCO, Physician-in-Chief of the Hartford HealthCare Cancer Institute, Chair, Co-Host Committee, ASCO Breakthrough 2023
PANELISTS:
- Dr. Lillian Siu, Professor, University of Toronto; Chair, Program Committee, ASCO Breakthrough 2023
- Dr. David Lebwohl, CMO, Intellia Therapeutics Dr. Melvin Chua Lee Kiang, Associate Professor, National Cancer Centre Singapore; Chair-
- Elect, Program Committee, ASCO Breakthrough 2023